Human Papillomavirus (HPV) Upregulates the Cellular Deubiquitinase UCHL1 to Suppress the Keratinocyte's Innate Immune Response

PLoS Pathogens

Volumn 9, Issue 5, 2013, Pages

  Karim, Rezaul ^a   Tummers, Bart ^a   Meyers, Craig ^b   Biryukov, Jennifer L ^b   Alam, Samina ^b   Backendorf, Claude ^c   Jha, Veena ^a   Offringa, Rienk ^a,e   van Ommen, Gert Jan B ^a   Melief, Cornelis J M ^a   Guardavaccaro, Daniele ^d   Boer, Judith M ^a   van der Burg, Sjoerd H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c LEIDEN UNIVERSITY   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CPG OLIGODEOXYNUCLEOTIDE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; I KAPPA B KINASE GAMMA; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MESSENGER RNA; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PATTERN RECOGNITION RECEPTOR; PROTEIN KINASE R; RANTES; RETINOIC ACID INDUCIBLE PROTEIN I; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; UBIQUITIN THIOLESTERASE;

ARTICLE; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; INFLAMMATION; INNATE IMMUNITY; KERATINOCYTE; MICROARRAY ANALYSIS; NONHUMAN; PAPILLOMAVIRUS INFECTION; PHOSPHORYLATION; PLASMID; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK; RNA INTERFERENCE; UBIQUITINATION; VIRION; VIRUS TRANSCRIPTION; WART VIRUS; WESTERN BLOTTING;

3T3 CELLS; ANIMALS; CELLS, CULTURED; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, VIRAL; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNITY, INNATE; KERATINOCYTES; MICE; PAPILLOMAVIRUS INFECTIONS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; TNF RECEPTOR-ASSOCIATED FACTOR 3; TRANSCRIPTION FACTOR RELA; UBIQUITIN THIOLESTERASE; UBIQUITINATION; UP-REGULATION; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS;

EID: 84878509069     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003384     Document Type: Article

References (51)

1. zur Hausen H, (2002) Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2: 342-350.
2. Doorbar J, (2006) Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) 110: 525-541.
3. Frazer IH, (2009) Interaction of human papillomaviruses with the host immune system: a well evolved relationship. Virology 384: 410-414.
4. Richardson H, Kelsall G, Tellier P, Voyer H, Abrahamowicz M, et al. (2003) The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev 12: 485-490.
5. Takeuchi O, Akira S, (2009) Innate immunity to virus infection. Immunol Rev 227: 75-86.
6. Bhoj VG, Chen ZJ, (2009) Ubiquitylation in innate and adaptive immunity. Nature 458: 430-437.
7. Zhao T, Yang L, Sun Q, Arguello M, Ballard DW, et al. (2007) The NEMO adaptor bridges the nuclear factor-kappaB and interferon regulatory factor signaling pathways. Nat Immunol 8: 592-600.
8. Hasan UA, Bates E, Takeshita F, Biliato A, Accardi R, et al. (2007) TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol 178: 3186-3197.
9. Kalali BN, Kollisch G, Mages J, Muller T, Bauer S, et al. (2008) Double-stranded RNA induces an antiviral defense status in epidermal keratinocytes through TLR3-, PKR-, and MDA5/RIG-I-mediated differential signaling. J Immunol 181: 2694-2704.
10. Karim R, Meyers C, Backendorf C, Ludigs K, Offringa R, et al. (2011) Human Papillomavirus Deregulates the Response of a Cellular Network Comprising of Chemotactic and Proinflammatory Genes. Plos One 6: e17848.
11. Ablasser A, Bauernfeind F, Hartmann G, Latz E, Fitzgerald KA, et al. (2009) RIG-I-dependent sensing of poly(dA:dT) through the induction of an RNA polymerase III-transcribed RNA intermediate. Nat Immunol 10: 1065-1072.
12. Chiu YH, Macmillan JB, Chen ZJ, (2009) RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway. Cell 138: 576-591.
13. Meyers C, Mayer TJ, Ozbun MA, (1997) Synthesis of infectious human papillomavirus type 18 in differentiating epithelium transfected with viral DNA. J Virol 71: 7381-7386.
14. McLaughlin-Drubin ME, Christensen ND, Meyers C, (2004) Propagation, infection, and neutralization of authentic HPV16 virus. Virology 322: 213-219.
15. Conway MJ, Alam S, Ryndock EJ, Cruz L, Christensen ND, et al. (2009) Tissue-spanning redox gradient-dependent assembly of native human papillomavirus type 16 virions. J Virol 83: 10515-10526.
16. Wang D, Fang L, Li K, Zhong H, Fan J, et al. (2012) Foot-and-Mouth Disease Virus 3C Protease Cleaves NEMO To Impair Innate Immune Signaling. J Virol 86: 9311-9322.
17. Fliss PM, Jowers TP, Brinkmann MM, Holstermann B, Mack C, et al. (2012) Viral mediated redirection of NEMO/IKKgamma to autophagosomes curtails the inflammatory cascade. PLoS Pathog 8: e1002517.
18. Alloul N, Sherman L, (1999) The E2 protein of human papillomavirus type 16 is translated from a variety of differentially spliced polycistronic mRNAs. J Gen Virol 80 (Pt 1) (): 29-37.
19. Sherman L, Alloul N, (1992) Human papillomavirus type 16 expresses a variety of alternatively spliced mRNAs putatively encoding the E2 protein. Virology 191: 953-959.
20. Liu Y, Fallon L, Lashuel HA, Liu Z, Lansbury PT Jr, (2002) The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell 111: 209-218.
21. Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A, et al. (2003) CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 424: 793-796.
22. Shembade N, Ma A, Harhaj EW, (2010) Inhibition of NF-kappaB signaling by A20 through disruption of ubiquitin enzyme complexes. Science 327: 1135-1139.
23. Kayagaki N, Phung Q, Chan S, Chaudhari R, Quan C, et al. (2007) DUBA: a deubiquitinase that regulates type I interferon production. Science 318: 1628-1632.
24. Kovalenko A, Chable-Bessia C, Cantarella G, Israel A, Wallach D, et al. (2003) The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 424: 801-805.
25. Li S, Zheng H, Mao AP, Zhong B, Li Y, et al. (2010) Regulation of virus-triggered signaling by OTUB1- and OTUB2-mediated deubiquitination of TRAF3 and TRAF6. J Biol Chem 285: 4291-4297.
26. Wertz IE, O'Rourke KM, Zhou H, Eby M, Aravind L, et al. (2004) De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 430: 694-699.
27. Zhang SQ, Kovalenko A, Cantarella G, Wallach D, (2000) Recruitment of the IKK signalosome to the p55 TNF receptor: RIP and A20 bind to NEMO (IKKgamma) upon receptor stimulation. Immunity 12: 301-311.
28. Sebban-Benin H, Pescatore A, Fusco F, Pascuale V, Gautheron J, et al. (2007) Identification of TRAF6-dependent NEMO polyubiquitination sites through analysis of a new NEMO mutation causing incontinentia pigmenti. Hum Mol Genet 16: 2805-2815.
29. Takami Y, Nakagami H, Morishita R, Katsuya T, Cui TX, et al. (2007) Ubiquitin carboxyl-terminal hydrolase L1, a novel deubiquitinating enzyme in the vasculature, attenuates NF-kappaB activation. Arterioscler Thromb Vasc Biol 27: 2184-2190.
30. Hiscott J, Nguyen TL, Arguello M, Nakhaei P, Paz S, (2006) Manipulation of the nuclear factor-kappaB pathway and the innate immune response by viruses. Oncogene 25: 6844-6867.
31. Mohamed MR, McFadden G, (2009) NFkB inhibitors: strategies from poxviruses. Cell Cycle 8: 3125-3132.
32. Chen RA, Ryzhakov G, Cooray S, Randow F, Smith GL, (2008) Inhibition of IkappaB kinase by vaccinia virus virulence factor B14. PLoS Pathog 4: e22.
33. Stack J, Haga IR, Schroder M, Bartlett NW, Maloney G, et al. (2005) Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence. J Exp Med 201: 1007-1018.
34. Alff PJ, Sen N, Gorbunova E, Gavrilovskaya IN, Mackow ER, (2008) The NY-1 hantavirus Gn cytoplasmic tail coprecipitates TRAF3 and inhibits cellular interferon responses by disrupting TBK1-TRAF3 complex formation. J Virol 82: 9115-9122.
35. Wu S, Xie P, Welsh K, Li C, Ni CZ, et al. (2005) LMP1 protein from the Epstein-Barr virus is a structural CD40 decoy in B lymphocytes for binding to TRAF3. J Biol Chem 280: 33620-33626.
36. Scheffner M, Whitaker NJ, (2003) Human papillomavirus-induced carcinogenesis and the ubiquitin-proteasome system. Semin Cancer Biol 13: 59-67.
37. Isaacson MK, Ploegh HL, (2009) Ubiquitination, ubiquitin-like modifiers, and deubiquitination in viral infection. Cell Host Microbe 5: 559-570.
38. Chen F, Sugiura Y, Myers KG, Liu Y, Lin W, (2010) Ubiquitin carboxyl-terminal hydrolase L1 is required for maintaining the structure and function of the neuromuscular junction. Proc Natl Acad Sci U S A 107: 1636-1641.
39. Fang Y, Fu D, Shen XZ, (2010) The potential role of ubiquitin c-terminal hydrolases in oncogenesis. Biochim Biophys Acta 1806: 1-6.
40. Boone DL, Turer EE, Lee EG, Ahmad RC, Wheeler MT, et al. (2004) The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol 5: 1052-1060.
41. Wilkins C, Gale M Jr, (2010) Recognition of viruses by cytoplasmic sensors. Curr Opin Immunol 22: 41-47.
42. Rolen U, Kobzeva V, Gasparjan N, Ovaa H, Winberg G, et al. (2006) Activity profiling of deubiquitinating enzymes in cervical carcinoma biopsies and cell lines. Mol Carcinog 45: 260-269.
43. zur Hausen H, (2009) Papillomaviruses in the causation of human cancers- a brief historical account. Virology 384: 260-265.
44. Park JS, Kim EJ, Kwon HJ, Hwang ES, Namkoong SE, et al. (2000) Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis. J Biol Chem 275: 6764-6769.
45. Huang SM, McCance DJ, (2002) Down regulation of the interleukin-8 promoter by human papillomavirus type 16 E6 and E7 through effects on CREB binding protein/p300 and P/CAF. J Virol 76: 8710-8721.
46. Spitkovsky D, Hehner SP, Hofmann TG, Moller A, Schmitz ML, (2002) The human papillomavirus oncoprotein E7 attenuates NF-kappa B activation by targeting the Ikappa B kinase complex. J Biol Chem 277: 25576-25582.
47. Barnard P, McMillan NA, (1999) The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-alpha. Virology 259: 305-313.
48. Baldwin AS, (2001) Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 107: 241-246.
49. An J, Mo D, Liu H, Veena MS, Srivatsan ES, et al. (2008) Inactivation of the CYLD deubiquitinase by HPV E6 mediates hypoxia-induced NF-kappaB activation. Cancer Cell 14: 394-407.
50. Fischer DF, Gibbs S, van De Putte P, Backendorf C, (1996) Interdependent transcription control elements regulate the expression of the SPRR2A gene during keratinocyte terminal differentiation. Mol Cell Biol 16: 5365-5374.
51. Ashida H, Kim M, Schmidt-Supprian M, Ma A, Ogawa M, et al. (2010) A bacterial E3 ubiquitin ligase IpaH9.8 targets NEMO/IKKgamma to dampen the host NF-kappaB-mediated inflammatory response. Nat Cell Biol 12: 66-73; sup pp 61-69.